On Wednesday October 30th, London Stock Exchange welcomed RTW Venture Fund Limited to its first day of trading on the Specialist Fund Segment of the Main Market with a starting NAV and market capitalization of $168M.
Trading under the ticker “RTW”, RTW Venture Fund Limited seeks to achieve positive absolute performance and superior long-term capital appreciation through forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a portfolio of investments across a range of businesses, each pursuing the development of assets that have the potential to enhance quality of life and extend patient life. The Investment Manager, RTW Investments, is led by partners Roderick Wong, Naveen Yalamanchi, Stephanie Sirota, and Sabera Loughran, and has a strong track record, having delivered public-private annualized returns of 29% over 10 years.
Roderick Wong M.D., Managing Partner and Chief Investment Officer of RTW Investments, LP, said:
“We are excited to be listing RTW Venture Fund Limited on the London Stock Exchange, and to have the opportunity to grow our presence with UK investors. This financing supports our existing work to identify and help build transformative drug and medtech companies that aim to improve and extend patients’ lives. We also look forward to deepening our efforts with innovative companies in the UK, as well as internationally.”
William Simpson, chairman of RTW Venture Fund Limited, said:
“I am delighted to be chairing this new fund that aims to support the growth of world-class biotech and medtech companies. Our Investment Manager, RTW Investments, is a leading US-based healthcare investment firm, with a strong track record of backing innovative therapeutic assets. I look forward to the RTW Investments team applying its long- term focus and science-driven approach to capture value for investors and, ultimately, to benefit patients.”
Barclays and JP Morgan Cazenove acted as Global Coordinators and Joint Bookrunners.